pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·3d ago·1 min read
save

‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors

Nov 6, 2026·read at Fierce Biotech ↗

The San Diego-based biotech has shown that when its vaccine-like therapeutic, N17350, is injected directly into the tumor, the candidate is even able to clear cancer lesions that are distant from the injected tumor.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 9h agoZura scraps hidradenitis suppurativa program after phase 2 miss, sinking stockFierce Biotech
  • 9h agoJ&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depressionFierce Biotech
  • 10h agoSanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from ChinaFierce Biotech
  • 10h agoSpruce spins out preclinical endocrinology program into newly formed AdrenyxFierce Biotech
  • 11h agoKyorin pens $140M deal for Japan rights to Edesa’s phase 3 respiratory drugFierce Biotech